Document Detail


Multiple sclerosis, interferon beta and clinical thyroid dysfunction.
MedLine Citation:
PMID:  12580868     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of this study was to investigate frequency and presentation of clinical thyroid dysfunction in patients treated with interferon beta (IFN-beta). We have collected the cases of clinical thyroid dysfunction in 700 consecutive patients receiving IFN-beta for multiple sclerosis (MS). Five patients (four women, one man) treated with IFN-beta1b developed hyperthyroidism. Three of them have secondary progressive MS, and two have relapsing-remitting MS. It was necessary to stop IFN-beta in three cases; these patients still require carbimazole after several months. In the two other cases, hyperthyroidism disappeared spontaneously. Two patients (one man and one woman) treated with IFN-beta1a developed hypothyroidism. One of them required l-thyroxine. Lastly, an increased thyroid volume without modification of thyroid hormones plasma levels was discovered in a patient receiving IFN-beta1a. Among patients treated with IFN-beta, clinical thyroid dysfunction is much rarer than laboratory thyroid dysfunction. However, this side-effect is sometimes severe.
Authors:
A Kreisler; J de Seze; T Stojkovic; B Delisse; M Combelles; A Vérier; P Hautecoeur; P Vermersch;
Related Documents :
8364878 - Increased uptake of iodine-131 in metastases of differentiated thyroid carcinoma associ...
16872798 - Papillary thyroid microcarcinoma (ptmc): prognostic factors, management and outcome in ...
19375868 - Increased prevalence of antibodies to central nervous system tissue and gangliosides in...
1369638 - Patient selection criteria for electrostimulation of salivary production in the treatme...
16377948 - Recovery process of immediate prolonged posttraumatic coma following severe head injury...
175658 - Trachoma in a rural haitian community.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Acta neurologica Scandinavica     Volume:  107     ISSN:  0001-6314     ISO Abbreviation:  Acta Neurol. Scand.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-12     Completed Date:  2003-04-15     Revised Date:  2006-08-16    
Medline Journal Info:
Nlm Unique ID:  0370336     Medline TA:  Acta Neurol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  154-7     Citation Subset:  IM    
Affiliation:
Department of Neurology, Lille University Hospital, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antithyroid Agents / therapeutic use
Female
Goiter / chemically induced,  complications,  drug therapy
Humans
Hyperthyroidism / chemically induced,  complications,  drug therapy
Hypothyroidism / chemically induced,  complications,  drug therapy
Interferon-beta / adverse effects*
Male
Multiple Sclerosis, Chronic Progressive / complications*,  drug therapy
Multiple Sclerosis, Relapsing-Remitting / complications*,  drug therapy
Thyroid Diseases / chemically induced*,  complications,  diagnosis
Thyroxine / therapeutic use
Chemical
Reg. No./Substance:
0/Antithyroid Agents; 145155-23-3/interferon beta-1b; 145258-61-3/interferon beta 1a; 7488-70-2/Thyroxine; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Platelet serotonin transporter in stroke patients.
Next Document:  Antimigraine drug consumption in Spain (1990-2000).